AZ appoints Genentech’s Sean Bohen as chief medical officer
pharmafile | August 25, 2015 | Appointment | Manufacturing and Production, Research and Development, Sales and Marketing | AstraZeneca, Briggs Morrison, Sean Bohen
AstraZeneca has appointed Dr Sean Bohen as executive vice president of global medicines development and chief medical officer.
Dr Bohen will be responsible for the progress of AstraZeneca’s portfolio of small molecules and biologics investigational medicines through late-stage development to regulatory approval. Bohen will join the company on 15 September.
As chief medical officer, he will be responsible for patient safety across the entire AstraZeneca and Medimmune portfolio.
Bohen joins AstraZeneca from Genentech where he was instrumental in bringing a large number of new medicines to patients, in particular for cancer, and led activities to incorporate diagnostics into clinical programmes.
At Genetech Bohen was most recently senior vice president of early development. He oversaw preclinical and clinical development programmes across all therapy areas, including oncology, respiratory and autoimmune diseases, to deliver trial-ready drug candidates to late-stage development
Prior to joining Genentech, Bohen was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute.
AstraZeneca chief executive Pascal Soriot says: “I’m delighted to welcome Sean to AstraZeneca at a very exciting time for our company. Our continued strategic investment in science is driving momentum across all therapy areas. Sean is a tremendous scientist and an accomplished drug developer. His impressive expertise in key areas of our exciting pipeline, including oncology and immunology, will further strengthen and accelerate the delivery of new medicines for patients. His extensive diagnostics experience will also reinforce our efforts in precision medicine.”
Bohen replaces Briggs Morrison, who left AstraZeneca in June to become chief executive of Syndax Pharmaceuticals, a small biotech firm based in Waltham, Massachusetts.
Related Content
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
NICE approves AstraZeneca’s dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …
Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …
